Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

Exclusion Criteria

• •Non-type 2 diabetes mellitus: Type 1 diabetes mellitus, gestational diabetes history;
• •History of acute complications of diabetes (diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome or lactic acidosis);
• •History of chronic complications of severe diabetes (retinal proliferative disease, severe diabetic neuropathy or intermittent claudication confirmed by fundus examination during screening);
• •Patients who used systemic glucocorticoids within 3 months prior to screening had severe infections or major surgeries and transplants within 3 months;
• •Three or more episodes of hypoglycemia occurred in the six months prior to screening;
• •History of hyperthyroidism within 6 months before screening;
• •Severe cardiovascular disease. ;
• •Medical conditions that may significantly affect drug absorption, distribution, metabolism, and excretion within 2 weeks prior to screening;
• •Liver function tests abnormal;
• •Moderate or severe renal impairment;
• •Medical history or clinical evidence of pancreatic injury or pancreatitis, or abnormalities in lipase and amylase judged by investigators to be clinically significant;
• •Patients with a history of hypertension who regularly take antihypertensive therapy for over 4 weeks still have poor control, SBP \> 160 mmHg and (or) DBP \> 100 mmHg;
• •Patients with uncontrolled hyperlipidemia.